

ORUSH

Rush University System for Health

Liver Cancer Care at Rush

At Rush, our clinicians are skilled in the treatment of both primary and metastatic liver cancer. We provide patients with a comprehensive approach to care with a strong collaboration between our surgical, interventional radiology and oncology teams. Rush has the ability to provide both surgical and non-surgical treatment options, such as ablation, chemotherapy and radiation therapy, as well as access to the latest clinical trials. Other treatment options, such as transplantation, are also available.

A hallmark of our approach is our willingness and expertise in treating patients with advanced metastatic liver disease. Instead of offering these patients just care options, we often present them with a curative paradigm, largely due to our success in resecting extensive liver metastases with regenerative liver surgery. Rush is a national leader in this procedure; our surgeons have written landmark papers and speak on several panels across the world every year on this topic.

Why refer your patients here?

Pioneering clinical trials: Rush is participating in several clinical trials focused on bringing the latest, most effective chemotherapy treatments to the bedside for primary and metastatic liver tumors. In addition, Rush is involved in the novel, international DRAGON1 clinical trial, which evaluates the effectiveness of embolizing both the portal vein and hepatic veins (double embolization) on one side of the liver to catalyze faster and more extensive liver size and function growth.

Leaders in fibrolamellar carcinoma treatment: We have developed pioneering, lifechanging treatments for fibrolamellar carcinoma, a rare pediatric cancer. We employ novel immunotherapeutic combinations and portal vein/double vein embolization, a cutting-edge technique used in greater volume at Rush than anywhere in North America. Rush also treats the largest number of all cases of this rare type of cancer in the United States.

First-rate care: Rush was the first hospital in Chicago to introduce DOTATATE scanning and to offer peptide receptor radionuclide therapy for patients with neuroendocrine metastases.

Treatment leader of liver metastases: In 2019, Rush hosted the Chicago LIVERMET Symposium, which featured the latest innovations in the treatment of liver metastases. The conference was attended by expert clinicians who diagnose and treat metastatic liver disease across the United States.

Locations: Our providers are available to see patients at Rush University Medical Center and Rush South Loop in Chicago and Rush Oak Brook, Rush Oak Park and Rush Copley in Aurora.

Types of liver cancer we treat

Primary liver tumors

- · Cholangiocarcinoma
- Fibrolamellar carcinoma
- Hepatoblastoma
- Hepatocellular carcinoma

Metastatic liver tumors

- Colorectal metastases
- Liver metastases from other primary cancers
- Neuroendocrine metastases

Treatments

Embolization

- Chemoembolization
- Radioembolization

Local regional interventions

- Microwave ablation
- NanoKnife
- Tumor ablation

Radiation hepatectomy Regenerative liver therapy

Surgery

- Laparoscopic
- Open
- Robotic

Transplantation

Our Team



Bulent Arslan, MD Director

Vascular and Interventional Radiology

Clinical expertise Portal vein embolization

Radioembolization



Edie Chan, MD, FACS **Surgical Director** Liver Transplantation

Clinical expertise Hepatocellular carcinoma Liver transplantation



Sheila Eswaran, MD, MS **Clinical expertise** Hepatocellular carcinoma



Audrey Kam, MD Clinical expertise

their metastases



William Leslie, MD Clinical expertise



Thomas Kim, MD Gastrointestinal Radiation Oncology Clinical expertise

Stereotactic radiation of liver tumors and



Sam Pappas, MD, FACS Director Surgical Oncology Clinical expertise Cholangiocarcinoma



Srikumar Pillai, MD, FACS Director Pediatric Surgery Clinical expertise



Nancy Reau, MD **Section Chief** Hepatology **Associate Director**

Liver metastases





FEBS (HPB) Clinical expertise Cholangiocarcinoma Liver metastases Surgical oncology

Erik Schadde, MD, FACS,



Director Interventional Oncology Clinical expertise Double embolization Nanoknife

Jordan Tasse, MD

Locations

Rush University Medical Center 1725 W. Harrison St.

Chicago, IL 60612

Rush Lincoln Park 2835 N. Sheffield Ave. Chicago, IL 60657

Rush River North 539 N. Dearborn St. Chicago, IL 60654

Rush Oak Brook 2011 York Road Oak Brook, IL 60523

Rush Oak Park 610 S. Maple Ave. Oak Park, IL 60304

Rush Copley 2040 Ogden Ave. Aurora, IL 60504

To refer patients or request a consult, call (312) CANCER-1.

For more information, contact Jessica Ellison, RN **Manager of Clinical Operations**

Phone: (312) 942-4252 Email: jessica_ellison@rush.edu

